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ABSTRACT
Human Chronic Myelogenous Leukemia (CML) is a hematological stem cell 
disorder which is associated with activation of Bcr-Abl-Stat5 oncogenic pathway. 
Direct Bcr-Abl inhibitors are initially successful for the treatment of CML but over time 
many patients develop drug resistance. In the present study, the effects of CM363, 
a novel naphthoquinone (NPQ) derivative, were evaluated on human CML-derived 
K562 cells. CM363 revealed an effective cell growth inhibition (IC50 = 0.7 ± 0.5 µM)  
by inducing cancer cells to undergo cell cycle arrest and apoptosis. CM363 caused 
a dose- and time-dependent reduction of cells in G0/G1 and G2/M phases. This 
cell cycle arrest was associated with increased levels of cyclin E, pChk1 and pChk2 
whereas CM363 downregulated cyclin B, cyclin D3, p27, pRB, Wee1, and BUBR1. 
CM363 increased the double-strand DNA break marker γH2AX. CM363 caused a time-
dependent increase of annexin V-positive cells, DNA fragmentation and increased 
number of apoptotic nuclei. CM363 triggered the mitochondrial apoptotic pathway 
as reflected by a release of cytochrome C from mitochondria and induction of the 
cleavage of caspase-3 and -9, and PARP. CM363 showed multikinase modulatory 
effects through an early increased JNK phosphorylation followed by inhibition of 
pY-Bcrl-Abl and pY-Stat5. CM363 worked synergistically with imatinib to inhibit 
cell viability and maintained its activity in imatinib-resistant cells. Finally, CM363 
(10 mg/Kg) suppressed the growth of K562 xenograft tumors in athymic mice. 
In summary, CM363 is a novel multikinase modulator that offers advantages to 
circumvent imanitib resistance and might be therapeutically effective in Bcrl-Abl-
Stat5 related malignancies.
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INTRODUCTION
Chronic Myelogenous Leukemia (CML) is a 
hematological stem cell disorder characterized by 
excessive proliferation of cells of the myelogenous 
lineage [1]. The hallmark of CML is the Philadelphia 
chromosome, which arises from reciprocal translocation 
between chromosomes 9 and 22. The molecular 
consequence of this translocation is the replacement of 
the first exon of c-Abl with sequences from the Bcr gene 
resulting in a Bcr-Abl fusion gene whose protein product 
generates a constitutively activated tyrosine kinase. Found 
in 95% of patients with CML, Bcr-Abl is also present in 
approximately 5–10% of adults with acute leukemia for 
whom there is no evidence of antecedent CML. Bcr-Abl 
is considered necessary, but may not be sufficient, to cause 
malignant transformation in CML. Bcr-Abl activates 
intracellular signal transduction pathways that promote 
proliferation and genetic instability while suppressing 
apoptosis and weakening cellular adhesion [1]. 
Biochemical signaling pathways known to be activated 
by Bcr-Abl include the PI3K/AKT/mTOR pathway, CRK 
oncogene-like protein/focal adhesion kinase, the RAS/
RAF/MEK/ERK pathway, c-Jun NH2-terminal kinase/
stress-activated protein kinase (JNK/SAPK), and the 
Signal Transducer and Activator of Transcription (Stat)-
5 pathway [1–5]. Particularly, activation of Stat5 by Bcr/
Abl leads to increased expression of genes driving cell 
cycle progression, promoting survival, and oncogenesis 
signaling pathways downstream of Bcr-Abl kinase [6]. 
In contrast, deletion of Stat5 in Bcr-Abl+ cells induces 
apoptosis, even in Bcr-Abl tyrosine kinase inhibitors 
(TKI)-resistant cells. Furthermore, Stat5 is constitutively 
active in many forms of hematologic cancers [5], and, 
aside Bcr-Abl, it is a signaling hallmark of CML and its 
activity is associated with poor prognosis [7]. 
The tyrosine kinase inhibitor (TKI) imatinib 
mesylate (IM), an ATP-competitive selective inhibitor 
of Bcr-Abl, is the standard first-line therapy for all 
CML patients [8]. Particularly, 80% of newly diagnosed 
patients with chronic-phase CML have shown a complete 
cytogenetic response to treatment with IM over a median 
follow-up of 54 months. However, although the initial 
response rates are high, IM fails in up to 40% of patients 
because of disease resistance or unacceptable side 
effects which call for alternative therapies to treat CML 
patients. Both preclinical and clinical studies suggest 
that the induction of the apoptosis of Bcr-Abl+ leukemia 
cells by IM may be incomplete and patients can develop 
resistance to TKI [9]. The most frequently reported causes 
for TKI resistance are mutations in the kinase domain 
of Bcr-Abl. Other mechanisms include the increased 
expression of proteins such as Bcr-Abl or the drug 
transporter ABCB1, TP53 inactivation, elevated levels 
of granulocyte-macrophage-colony-stimulating factor 
(GM-CSF), or increased Stat5 activation [9]. To circumvent 
the resistance, more potent TKI have been approved 
(e.g., dasatinib and nilotinib). However, these compounds 
do not show therapeutic activities against all IM-resistant 
mutants of Bcr-Abl, and finally a long-term tolerability 
problem has emerged [8, 10]. Preclinical and clinical 
studies suggest that multikinase drugs (i.e., to target 
alternate Bcr-Abl kinase pathways) might produce better 
results than “selective” TKI because mitogenesis and drug 
resistance can occur, in part, via activation of alternate 
Bcr-Abl mitogenic signals [10, 11]. Therefore, the 
combination of TKI with multikinase inhibitors would be 
clinically relevant. Notably, the inhibition of phosphoStat5 
(pStat5) constitutes a suitable target to abrogate CML cell 
growth and other types of leukemias, and, it is considered 
an attractive target to overcome resistance to clinically 
used Bcr-Abl kinase inhibitors [12–14].
The biological activities and structural properties of 
naphthoquinone (NPQ) (mainly 1,4-napthtoquinones and 
their derivatives) have led to consider them as privileged 
structures in medicinal chemistry. NPQ-based derivatives 
have exhibited a wide variety of biological activities which 
include, among others, anti-inflammatory, cytotoxic, 
and anticancer activities. Particularly, NPQ derivatives 
have been shown to suppress Stat signaling pathway 
in cancer cells [15, 16]. Recently, we have discovered 
the compound CM363 [4-(1,6,11-trioxo-2,3,4,6,11,12-
hexahydro-1H-benzo[b]xanthen-12-yl)benzonitrile] [17], 
a synthetic NPQ-based derivative that was discovered by 
transcriptionally based assays and phenotypic cell based 
screening of a small molecules library. In this study, 
we report the anti-CML effects of CM363 in vitro and 
in vivo. CM363 was characterized as an inhibitor Bcr-
Abl-Stat5 signaling pathway that induces cell cycle arrest 
and apoptosis in CML cells. These effects are enhanced 
when CM363 is combined with IM. Notably, CM363 is 
equally effective against IM-sensitive and IM–resistant 
cells. These findings provide new insights into molecular 
and cellular mechanisms of a novel multikinase modulator 
in CML and suggest a potential therapeutic application of 
this compound in Bcr-Abl- and Stat5-related malignancies.
RESULTS 
CM363 inhibits viability of human leukemia cells
CM363 (Figure 1A) was discovered by high-
throughput cell based phenotypic screening of a proprietary 
small molecule library [17]. First, cells transfected with a 
Stat-response element driving expression of a luciferase 
reporter gene were used to interrogate that chemical library. 
From this approach, CM363 was found to inhibit Stat5- or 
Stat3- (Figure 1B) dependent reporter genes. However, 
CM363 had negligible effects on transcriptional activity 
that regulates constitutive expression of β-galactosidase 
or luciferase (data not shown) protein (Figure 1B), 
suggesting that CM363 does not inhibit transcription 
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factors broadly. Second, viability of exponentially 
growing cells, representative of hematological and solid 
tumors, was studied in the presence of CM363 for 48 h 
by using the MTT assay. CM363 was able to inhibit 
cell viability of all human leukemia cell lines tested 
(i.e., K562, MOLM.13, MV4.11, HEL, and HL60) 
with high efficacy (Table 1). Thus, IC50s for K562 
(IC50 = 0.7 ± 0.5 µM), HEL (IC50 = 1.3 ± 0.3 µM), 
and HL60 (IC50 = 1.3 ± 0.6 µM) cells (Figure 1C) were 
lower than that observed for some non-hematological 
(i.e., HeLa = 4.8 ± 0.4 µM) and non-malignant (i.e., MRC-
5 = 3.5 ± 0.01 µM and PBMC cells > 5 µM) cells (Table 
1 and Figure 1C). In vivo Live-Cell Imaging of K562 cells 
corroborated that CM363 (Figure 1D) caused a cytostatic 
effect on cell growth at concentrations lower than 1 µM 
(IC50AUC = 0.6 ± 0.3 µM) and induced a cytotoxic effect 
at higher concentrations (EC50AUC = 1.1 ± 0.4 µM). As 
expected [18], IM caused a cytostatic effect on K562 
cells growth (IC50AUC  = 0.2 ± 0.1 µM) (data not shown). 
Time-lapse movies and photomicrograph of each well 
confirmed the effects of CM363 on K562 cell proliferation 
(Figure 1E). Finally, viability and proliferation of K562 
cells were examined after cells were pulsed-exposed to 
1–3 µM CM363 for either 6–24 h, followed by CM363 
removal from medium, and then grown in the absence of 
CM363 for additional 1–2 days. Exposure of K562 cells to 
3 µM CM363 for 6 h followed by 48 h of cells cultured in 
CM363-free culture medium, caused a significant decrease 
of K562 cell viability (Figure 1F). Furthermore, when the 
effects of transient exposure to CM363 were analyzed 
by using the Live-Cell Imaging System (Figure 1G), 
we observed that 2 h of transient exposure to CM363 
(IC50AUC = 1.9 ± 0.5 µM) was enough to cause a cytostatic 
effect on K562 cells for additional 72 h. Taken together, 
these results suggest that CML cells are acutely sensitive 
to CM363 and that they cannot overcome the inhibitory 
effects on cell growth caused by a short-transient exposure 
to this novel NPQ derivative.
CM363 blocks cell cycle progression in human 
chronic myelogenous leukemia cells
To assess whether the decrease of the K562 cell 
growth induced by CM363 was the result of cell cycle 
blockade, an increase in cytotoxicity, or both, K562 
cells were treated with CM363 (0.1–1 µM) for different 
times and cell cycle profiles and apoptotic induction were 
analyzed. CM363 caused an increase in S phase and a 
reduction in G0/G1 and G2/M phases (Figure 2A–2C). 
To further investigate the mechanism of action of CM363, 
we analyzed the changes induced by this compound 
on proteins involved in cell cycle regulation [19, 20]. 
Blockage of cell cycle was associated with increased 
levels of cyclin E and increased phosphorylations of 
Checkpoint kinase (Chk)-1 and Chk2 (Figure 3). Notably, 
the expression level of phosphatase Cdc25C, which plays 
a critical role in the G2/M checkpoint [19], was reduced 
by CM363 (Figure 3). CM363 also reduced amounts 
of cyclin B, cyclin D3, p27, Wee1, BUBR1 as well as 
phosphorylation of retinoblastoma protein (Rb) whereas 
CDK2 levels remained unaffected (Figure 3). Importantly, 
CM363 increased the double-strand DNA break 
marker γH2AX which indicates that K562 cells cannot 
overcome cell cycle arrest and that they are destined for 
apoptosis (Figure 3).  
CM363 induces apoptosis in human chronic 
myelogenous leukemia cells
In addition to cell cycle arrest, CM363 reduced 
viability of K562 cells was associated with a time-
dependent increase of annexin V-positive cells 
(Figure 4A) and increased number of apoptotic nuclei 
(Figure 4B). CM363 also caused a time dependent release 
of cytochrome C from mitochondria (Figure 4C) and 
induction of the cleavage of caspase-3, -9, and poly(ADP-
ribose) polymerase (PARP) (Figure 4D), which suggests 
that CM363 triggered the mitochondrial apoptotic 
pathway [21]. Finally, we observed that CM363 reduced 
the expression level of myeloid cell leukemia 1 (Mcl-1), 
an anti-apoptotic member of the Bcl-2 family of proteins 
[22, 23].
CM363 inhibits Bcr-Abl-Stat5 and induces 
JNK signaling pathways in human chronic 
myelogenous leukemia cells
Several cell survival signaling pathways in 
CML cells have been shown to be modulated by Bcr-
Abl, including Jak/Stat, JNK, and PI3K/AKT/mTOR 
signaling pathways [3]. Therefore, we first analyzed the 
effects of CM363 on Bcrl-Abl-Stat5 signaling pathway. 
Constitutive activation of pTyr694-Stat5 (pYStat5) and 
pTyr177-Bcrl-Abl (pYBcr-Abl), which are critical for K562 
cell survival, were significantly inhibited after exposure 
to 5 µM CM363 for 6 h (Figure 5A). The inhibitory 
effect of CM363 on Bcrl-Abl was mainly due to reduced 
Bcr-Abl protein content. Interestingly, CM363-induced 
Bcr-Abl and Stat5 inhibition was associated with reduced 
pTyr1007/1008-Jak2 (pYJak2) and increased pTyr416-Src 
(pYSrc), mainly caused by declined and increased Jak2 
and Src total protein content, respectively (Figure 5B). 
To further support the hypothesis that CM363 was able to 
inhibit constitutive pYStat5 in leukemia cells, we assessed 
the effects of CM363 on HEL, a human erythroleukemia 
cell line harboring constitutive activation of Jak2/
Stat5 signaling pathway [24]. Accordingly, CM363 also 
inhibited pYStat5 in a time- and dose-dependent manner 
in HEL cells (data not shown). To support the hypotheses 
that CM363 was also able to inhibit cytokine-induced 
Stat5/3 activities, we first observed that when HEL cells 
were serum starved, EPO caused an increase of pYStat5 
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within 5 min, whereas CM363 inhibited this activity in a 
time- and dose-dependent manner (Figure 6A). Next, we 
used T47D cells, a human breast adenocarcinoma cell line 
which lacks constitutively active Stat but is biologically 
responsive to GH and IL6 which are activators of Stat5 
and Stat3 signaling pathway, respectively [25, 26]. T47D 
cells where treated with GH or IL6 at different times 
and then examined for pYStat5 (Figure 6B) or pTyr705-
Stat3 (pYStat3) (Figure 6C), respectively. GH induced 
pYStat5 within 10 minutes whereas IL-6 induced pYStat3 
within 30 min. Exposure of cells to CM363 for 1 h was 
sufficient to suppress GH-induced pYStat5 (Figure 6B) as 
well as IL-6-induced pYStat3 (Figure 6C). In agreement 
with inhibition of pYStat, CM363 suppressed GH- and 
IL-6-induced binding to DNA of Stat5 (Figure 7A) and 
Stat3 (Figure 7B), respectively. In addition, exposition 
of primary mouse macrophages to 3 µM CM363 for 
0.5 h caused complete inhibition of GM-CSF-induced 
Figure 1: CM363 reduces viability and growth of human leukemia cells. (A) Chemical structure of CM363; (B) Serum 
starved HEKGHR and HeLa/Stat3-luc cells were used to interrogate chemical library on Stat5 (●) and Stat3 (■) response element driving 
expression of a luciferase reporter gene, respectively. The expression vector for β-galactosidase protein (□) was used to control transfection 
efficiency. Then, cells were pretreated with vehicle or CM363 for 1 h followed by GH (for Stat5) or IL6 (for Stat3) for 7 h. Luciferase 
activity was measured as described in Material and Methods. (C) Cells were cultured in the presence of the indicated concentrations of 
CM363 for 48 h, and thereafter cell viability of K562 (●), HEL (■), HL60 (▲), Hela (∆), MRC5 (□), and PMBC (○) cells were determined 
by the MTT assay; (D) K562 cells were cultured in the absence (vehicle) or presence of the indicated concentrations of CM363 over 4-day 
period. The effects of CM363 on K562 cell proliferation (●) and cytotoxicity (■) were studied by using the Incucyte HD real-time system 
and data are represented as area under curve (AUC); (E) Representative photomicrographs of exponentially growing K562 cells in the 
absence (vehicle; VEH) or presence of CM363 for 48 h; (F) Exponentially growing K562 cells were pulsed-exposed to 1 or 3 µM CM363 
for either 6 or 24 h. Then, K562 cells were washed and grown in the absence of CM363 for additional 24 or 48 h, and cell viability was 
studied by using MTT assay; (G) Exponentially growing K562 cells were pulsed-exposed to 0.3, 1 or 3 µM CM363 for either 2 (●,○), 
6 (■,□) or 24 (▲,∆) h. Then, K562 cells were washed and cell proliferation (black symbols) and cytotoxicity (white symbols) were studied 
in the absence of CM363 for additional 3 days by using Incucyte HD real-time system. Data are represented as area under curve (AUC). 
Figures are representative of 2–3 independent experiments each one performed in triplicate. ***P < 0.001 versus vehicle-treated cells (VEH); 
*P < 0.05 versus vehicle-treated cells (VEH).
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(10 min) pYStat5 (data not shown). Finally, functional 
consequences of CM363 on K562 cells were shown by 
decreased mRNA levels of PIM (Figure 7C) and c-Myc 
(Figure 7D), two target genes of Bcrl-Abl-Stat5 signaling 
pathway [1].
In summary, these results indicate that CM363 
can inhibit both constitutive as well as cytokine-induced 
activation of Stat signaling pathway. Next, we analyzed 
the effects of CM363 on several RTKs and relevant 
signaling mediators in K562 cells. This analysis was 
performed after exposure of K562 cells to 5 µM CM363 
for 6 h, by using an antibody-based Human Phospho-
Kinase Array kit. The analyses revealed that of the 
proteins evaluated, only some of them were modified after 
exposition of K562 cells to CM363 (Figure 8A–8C). The 
most inhibited proteins involved member of MAPK (p38; 
ERK1/2), Stat (Stat5b) and cell cycle (Chk-2) signaling 
pathways; whereas CM363 increased phosphorylation of 
JNK (JNK1/2/3) and AKT [(Ser473-AKT1/2/3)] proteins. In 
accordance with Human Phospho-Kinase Array analyses, 
CM363 decreased the levels of pERK1/2 and p38MAPK 
under the level of phosphorylation in vehicle-treated cells 
(Figure 9A). Notably, the activation (phosphorylation) 
of JNK, which appears crucial for Bcr-Abl–induced 
cellular proliferation and transformation [27], was evident 
as early as 3 h after CM363 treatment and persisted for 
12 h (Figure 9A). The expression levels of total forms of 
ERK1/2, p38MAPK or JNK were no altered after CM363 
treatment. Finally, the modulatory effects of CM363 on 
components of the PI3K/AKT/mTOR pathway were also 
studied. Particularly, CM363 reduced S6 phosphorylation 
levels (pS6) [28] (Figure 9B), which suggests inhibition of 
protein synthesis in K562 cells [29]. 
Coadministration of CM363/IM interacts 
synergistically to inhibit cell viability in  
CML, circunvent resistance of CML to IM
To investigate whether a CM363/IM combination 
might provide enhanced activity, we firstly studied the 
effects of this combination on pYStat5. Exposition 
of K562 cells for 3 h to 3 µM CM363 and 0.05 µM 
IM, individually, exerted 20% and 40% inhibition on 
pYStat5. However, when these two drugs were combined 
Table 1: Effects of CM363 on blood and non-blood cancer cells
IC50 (µM)
Cell Line Mean ± SD
Raw 0.1 ± 0.2
HEK 0.6 ± 0.2
K562 0.7 ± 0.5
MOLM.13 0.7 ± 1.1
NCTC 1.1 ± 0.7
MV4.11 1.2 ± 1.1
HEL 1.3 ± 0.3
HL60 1.3 ± 0.6
T47D 1.3 ± 1.2
PC3 1.5 ± 1.0
MG63 1.6 ± 0.9
MCF7 1.7 ± 1.1
SKBR3 2.6 ± 0.8
HCT-15 3.3 ± nd
L1210 3.4 ± 0.4
U-2 OS 4.3 ± 1.2
HeLa 4.8 ± 0.4
MRC.5 3.5 ± 0.0
PMBC > 5
Cells were treated with vehicle (0.05% DMSO) or CM363 (0.01 to 10 µM) for 48 h. Cell viability was assessed by MTT assay 
as described in Material and Methods (nd: not determined).
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virtually eliminated pYStat5 (Figure 10A). Secondly, we 
investigated a potential enhanced action of a CM363/IM 
combination on inhibiting cell survival. When CM363 
and IM were combined we observed a greater inhibition 
of cell survival compared to either drug used alone 
(Figure 10B). In another set of experiments, we utilized 
a constant ratio combination design [5(CM363):1(IM)] to 
determine whether these two drugs may act synergistically 
on inhibiting K562 cells survival. Isobologram and Chou-
Talalay analysis of the combination index [30] showed 
that CM363 and IM acted synergistically in inducing 
antiproliferative effects (combination index (CI) for 
ED50 = 0.4 ± 0.2 and CI for ED75 = 0.6 ± 0.3) (Figure 10C). 
To assess the broadness of the CM363 inhibitor, we 
determined its activity against IM-resistant CML-derived 
cell lines. The IM resistant K562-R [31] and KBTI [32] 
cells and the IM sensitive K562 cells counterpart were 
treated with increasing concentrations of CM363 or IM 
for 24–96 h. Notably, IC50 of IM needed for inhibit viable 
cells was almost 25 times higher in the K562-R cells than 
in the IM sensitive K562 cells counterpart (Figure 10D). 
However, both K562 as well as K562-R cells showed 
equivalent sensitivity to CM363. Inhibition was detected 
for concentration of CM363 as low as 0.3 µM, and the 
IC50 values were close to 0.6 µM for both clones. CM363 
was also active against IM-resistance KBTI human cells 
[32] (data not shown). Interesting, KBTI cells showed a 
partial resistance to CM363, suggesting that CM363 has 
also some inhibitory activity against the Bcr-Abl kinase 
expressed by CML cells. In vivo Live-Cell Imaging of 
K562 cells corroborated that CM363 caused a cytostatic 
effect on IM sensitive (IC50AUC = 0.6 ± 0.3 µM) as 
Figure 2: CM363 blocks cell cycle progression in human chronic myelogenous leukemia cells.  K562 cultures were treated 
with different doses of CM363 (A) or with 1 µM CM363 for 1–3 days (B). Subpopulation of cells (C) were quantified as percentage of 
cells in the sub-regions G0, M o S by fluorescence flow cytometry as described in Material and Methods. Figures are representative of two 
independent experiments each one performed in triplicate.
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well as IM resistant (IC50AUC = 0.5 ± 0.1 µM) K562 
cells at concentrations lower than 1 µM (Figure 10E). 
Surprisingly, higher concentration of CM363 caused a 
cytotoxic effect on IM sensitive K562 cells whereas it was 
cytostatic on IM resistance K562-R cells (Figure 10E). 
CM363 inhibits growth of human CML 
xenografts
Finally, we also determined whether CM363 
administration could suppress the growth of K562 
tumor xenografts in NOD-SCID mice [33]. Volume 
of the tumors established in mice in the control group 
(vehicle) increased in a consistent manner throughout 
the 25 days study period (Figure 11A). As expected the 
administration of the positive control compound IM (40 
mg/kg, orally) produced a pronounced and statistically 
significant reduction (P = 0.039 day 4 and P = 0.008 
day 25, compared to control group) in tumor growth 
(Figure 11A). Administration of CM363 (10 mg/kg, i.p.) 
also produced a pronounced, and statistically significant 
reduction (P = 0.004 day 4 and P = 0.007 day 25 
compared to control group) in tumor growth (Figure 11A). 
Interestingly, no significant body weight reduction was 
associated with CM363 treatment (Figure 11B).
DISCUSSION
The NPQ-based derivatives are considered as 
privileged chemical structures to develop antitumor 
agents [15, 16]. In fact, some quinone-antitumor agents 
have been used to treat solid tumors (e.g., doxorubicin) 
or acute lymphoblastic and myeloblastic leukemias 
(e.g., daunorubicin). Particularly, NPQ derivatives 
(e.g., shikonin, plumbagin, LQB-118) produce CML cell 
death with µM, low µM or sub-µM IC50 values [34–36]. 
However, the potential effects of these NPQ derivatives 
on normal or non-malignant human cells were not 
investigated, so we cannot rule out the possibility that 
they may cause certain degree of toxicity in non-cancer 
cells. In the present work, we investigated, in vitro and 
in vivo, the potential antileukemic properties of a new 
NPQ-based derivative named CM363. The structural 
features shared by CM363 with other well-known 
kinase inhibitors (e.g., CYT387, WP1066, LY5, 
tofacitinib, imatinib) are cyano groups and aromatic rings 
Figure 3: CM363 modulates proteins involved in cell cycle regulation. K562 cells cultures were exposed for 6, 12, 24, 48 hours 
to CM363 (1 µM). Then, whole cell extracts were obtained and proteins involved in cell cycle regulation were analyzed by immunoblotting. 
Figures are representative of two independent experiments.
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[37–40]. CM363 effectively inhibits the growth of human 
hematological cancer cells with low µM (HL60 and HEL 
cells) or sub- µM (K562 cells) IC50, and with a higher 
efficacy than on other hematological or non-hematological 
cancer cells. In contrast, human PBMC and non-malignant 
lung fibroblast MRC-5 were less sensitive to inhibition of 
cell viability by CM363. Interestingly, CM363 was able to 
induce long term inhibitory effects on K562 cell growth 
after they were transiently exposed to CM363. These 
data suggest an anti-cancer selectivity for leukemia cells 
and that CML cells are acutely sensitive to NPQ-based 
derivative CM363.
The molecular hallmark of CML is the presence 
of the constitutively activated tyrosine kinase Bcr-Abl, 
which is the causative factor in the pathophysiology of 
CML [1]. Bcr-Abl/Jak2/Stat5 activity in CML leads to 
increased expression of genes driving promoting survival, 
cell cycle progression, and oncogenic signaling pathways 
[5, 12–14]. However, both preclinical and clinical studies 
suggest that cure of CML patients by direct TKI may be 
incomplete, because of disease resistance to therapy and 
unacceptable side effects [8]. Interestingly, Jak2/Stat5 
signaling pathway is activated in IM-sensitive as well as 
IM-resistance Bcr-Abl+ cells [10]. In contrast, deletion of 
Jak2 or Stat5 in IM-sensitive and IM-resistant Bcr-Abl+ 
cells resulted in reduced colony formation and apoptosis 
[41]; therefore, Jak2/Stat5 inhibitors may be useful for 
CML therapy and the combination of TKI with CM363 
might offer advantages to circumvent resistance to direct 
Bcr-Abl inhibitors. NPQ-based derivatives have been 
Figure 4: CM363 induces apoptosis in K562 cells. (A) K562 were exposed for 1, 2, 3 days to CM363 (1 µM) to determine 
translocation of phosphatidylserine to the cell surface using the annexin V-FITC; (B) Photomicrographs of representative fields of K562 
cells stained with bisbenzimide trihydrochloride to evaluate nuclear chromatin condensation after treatment for 24 and 36 h with CM363 
(5 µM); K562 cultures were exposed for different times to CM363 (5 µM) and (C) cytosolic (cytochrome C) or (D) whole cell (PARP 
and pro-caspases 3, -8, and -9) extracts were analyzed by immunoblotting. Densitometric results from immunosignal values of cytosolic 
citochrome c relative to β-Actin are shown. β-Actin was used as a loading control. (E) Time-dependent effects of CM363 on Mcl-1 were 
studied by immunobloting. Figures are representative of two-three independent experiments. ***P < 0.001 versus vehicle-treated cells 
(VEH); *P < 0.05 versus vehicle-treated cells (VEH).
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shown to suppress Stat signaling pathway in cancer 
cells [16, 34–36]. However, the potential effects of these 
compounds on Bcr-Abl/Jak2/Stat5 signaling pathway in 
CML have not been previously investigated. In the present 
study, we demonstrated that CM363 showed antitumoral 
efficacy in IM-sensitive as well as IM-resistant cells 
and that the combinatory effect of IM with CM363 was 
more effective to reduce viability and phosphorylation of 
Bcr-Abl/Stat5. Moreover, we also observed that CM363 
reduced Jak2 phosphorylation in K562 cells. Previous 
studies have demonstrated that several NPQ-based 
derivatives can cause apoptosis in CML cells through 
induction of intrinsic mitochondria-dependent pathway 
[34, 36]. Similarly, we have demonstrated that exposure 
of the human CML cell line K562 to CM363 led to the 
induction of apoptosis as indicated by an increased 
annexin V binding as well as release of cytochrome c 
from the mitochondria into the cytoplasm, activation 
of caspases 3 and 9, and PARP cleavage. In contrast, 
CM363 did not activated caspase 8, which acts as initiator 
caspase in the extrinsic pathway of apoptosis. Previous 
studies have reported that Bcr-Abl inhibits apoptosis 
in CML cells through the regulation (expression and/or 
activation) of members of the Bcl-2 family of apoptosis 
modulators [22, 42, 43]. Particularly relevant in leukemia 
are the proapoptotic protein Bax, the antiapoptotic protein 
Bcl-xL, which prevents cytoplasmatic release of 
cytocrome c and, the antiapoptotic protein Mcl-1, which 
is able to bind to caspases in order to inhibit apoptosis 
signaling. Interestingly, it has been shown that Bcr-
Abl/Stat5 inhibition induces apoptosis in CML cells by 
supressing Stat5-dependent transcriptional regulation of 
Bcl-2 family members such as Mcl-1 [22] and Bcl-xL [43]. 
In the present study, we showed that CM363 inhibited Bcr-
Abl/Stat5 signaling pathway which was associated with 
decreased expression of Mcl-1 and increased expression of 
Figure 5: CM363 inhibits constitutive Bcrl-Abl-Stat5 signaling pathway. (A) K562 cultures were incubated with vehicle 
(VEH) or CM363 (5 µM) for indicated times. Then, immunoblotting analyzes were performed to detect the phosphorylated (pY) and total 
levels of Bcr-Abl, Bcr (upper and middle panel, respectively) and Stat5 (lower panel). (B) K562 cultures were incubated with vehicle 
or CM363 (5 µM) for indicated times. Then, immunoblotting analyzes were performed to detect the phosphorylated (pY) and total forms 
levels of Jak2 and Src proteins. Densitometric cuantification from immunosignal values of phospho and total proteins relative to β-Actin 
(VEH: fold 1) are shown. Figures are representative of two independent experiments each one performed in duplicate. ***P < 0.001 versus 
vehicle-treated cells (VEH). **P < 0.01 versus vehicle-treated cells (VEH); *P < 0.05 versus vehicle-treated cells (VEH).
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Bax and increased cytochrome realease from mitochondia. 
Therefore, one of the potential mechanisms that may 
explain the CM363 activation of intrinsic apoptotic 
pathway [44] in K562 cells is the dual inhibition of 
Bcr-Abl and Jak2 to whose activities Stat5 phosphorylation 
is linked. Bcr-Abl signaling is also linked to activation 
of the RAS/RAF/MEK/ERK, JNK, and the PI3K/AKT/
mTOR pathways [1, 2, 4, 5]. The balance between the 
ERK1/2 cascade and p38MAPK and JNK pathways can 
determine whether the cells live or die. ERK1/2 in most 
cases exerts cytoprotective effects, whereas the JNK and 
p38 have generally been associated with pro-apoptotic 
actions [45]. However, p38MAPK signaling has also been 
shown to enhance survival, cell growth and differentiation. 
Therefore, the role of p38MAPK in apoptosis is dependent 
on cell types and stimuli [46]. Previous studies have 
reported that ERK1/2 inhibition causes apoptosis in 
K562 cells [47]. In the present work, we observed 
that Bcr-Abl inhibition caused by CM363 resulted in 
a downregulation of ERK1/2 phosphorylation which 
suggest that this mechanism may contribute to CM363-
mediated apoptosis in K562 cells. Recent studies have 
shown that JNK activation is required for stress-induced 
release of mitochondrial cytochrome c and for apoptosis 
mediated by intrinsic signaling pathway [45]. Moreover, 
phosphorylation of prosurvival Bcl-2 by JNK disrupts the 
binding motif of Bcl-2 and makes it unable to antagonize 
Bax [48]. Interestingly, shikonin, a NPQ-based derivative, 
has been shown to induce the intrinsic apoptosis pathway 
in K562 cells through JNK activation [34]. In the current 
Figure 6: CM363 inhibits cytokine-induced tyrosine phosphorylations of Stat5 and Stat3. (A) Serum-deprived HEL cells 
were pre-incubated with CM363 (5 µM) for indicated times (left panel) or treated with different doses of CM363 for 3 h (right panel). 
Then, HEL cells were treated with EPO (10 units/ml) for 5 min followed by immunoblotting analyses of phosphorylated (pY) and total 
forms of Stat5. Densitometric analyses of pYStat5 relative to total Stat5 levels are shown. (B) Serum-deprived T47D cells were pre-
incubated with CM363 (5 µM) for indicated times (left panel) or treated with different doses of CM363 for 1 h (right panel). Then, T47D 
were treated with GH (50 nM) for 10 min followed by immunoblotting analyses of phosphorylated and total Stat5 levels. Densitometric 
analyses of pYStat5 relative to total Stat5 levels are shown. (C) Serum-deprived T47D cells were pre-incubated with CM363 (5 µM ) for 
indicated times (left panel) or treated with different doses of CM363 for 1 h (right panel). Then, T47D were treated with IL-6 (25 ng/ml) 
for 30 min followed by immunoblotting analyses of phosphorylated (pY) and total Stat3 levels. Densitometric analyses of pYStat3 relative 
to total Stat3 levels are shown. Figures are representative of two independent experiments each one performed in duplicate. ***P < 0.001 
versus EPO (A), GH (B) or IL-6 (C) stimulated cells; **P < 0.01 versus EPO (A) or IL-6 (C) stimulated cells.
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study we show that CM363 inhibits Bcr-Abl/Stat5 and 
induces JNK phosphorylation, so we cannot rule out 
the possibility that both mechanisms are contributing 
simultaneously to CM363-induced apoptosis. CM363 
reduced cell viability was also associated with modulation 
of PI3K/AKT/mTOR pathway [3]. We observed that 
CM363 reduced S424S6, a ribosomal protein that is 
phosphorylated in a Bcr-Abl- and PI3K/mTOR-dependent 
manner in Bcr-Abl+ cell lines [28]. Furthermore, CM363 
increased S473AKT, a phosphorylation that has been linked 
to inhibition of protein synthesis [29]. Therefore, these 
findings also support the hypothesis that the mechanism 
of CM363 action in K562 cells was linked, directly or 
indirectly, to inhibition of protein synthesis. 
The mechanism of action of CM363 on K562 cells 
also involved arrest of cell cycle with augmented S phase 
and reduced G0/G1 and G2/M phases. These actions were 
associated with effects of CM363 on expression levels 
and/or phosphorylation of several proteins involved in cell 
cycle progression [20, 21, 49]. The onset of mitosis in the 
Figure 7: CM363 inhibits cytokine-induced DNA-binding activities of Stat5 and Stat3. (A) Serum-deprived T47D cells 
were pre-incubated with CM363 (5 µM) for 1 h followed by GH (50 nM) for 10 min or (B) by IL-6 (25 ng/ml) for 30 min. Then, 
nuclear protein extracts were assayed by immunoblotting to detect the phosphorylated and total levels of Stat5 (A; upper panel) and Stat3 
(B; upper panel), respectively. Nuclear proteins from CM363 and GH/IL-6-treated T47D cells were analyzed to measure the binding of 
Stat5b (A; lower panel) or Stat3 (B; lower panel) to DNA by using ELISA as described in Materials and Methods. β-Actin was used as a 
loading control. K562 cells were incubated with vehicle (VEH), CM363 (3 µM) or IM (1 µM) for indicated times. Then, mRNA levels of 
(C) PIM and (D) c-Myc were analyzed. Figures are representative of two independent experiments each one performed in triplicate.*P < 
0.05 versus vehicle-treated cells; **P < 0.01 versus vehicle-treated cells; $P < 0.01 versus GH (A) or IL-6 (B) stimulated cells; ***P < 0.001 
versus vehicle-treated cells.
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eukaryotic cell cycle requires the coordinated activation of 
multiple M phase-inducing protein kinases in a process in 
which the activation of cyclin-dependent kinase (CDK)-1/
cyclin B complex plays a central role [19, 50]. Activation 
of this complex results from dephosphorylation of CDK1 
by the protein phosphatase Cdc25. Interestingly, CM363 
reduced the expression level of cyclin B and Cdc25. In 
addition, CM363 increased phosphorylation of Chk1 
and Chk2, two checkpoint kinases that inactivate Cdc25 
by phosphorylation or activates its degradation [19, 50]. 
Therefore, a reduced expression of Cdc25 together with 
an inactivation of Cdc25C by phosphorylation, most 
likely contribute to inhibition of mitotic entry by CM363. 
Moreover, many of the most potent CDC25 inhibitors 
are, similarly to CM363, quinone-containing compounds 
[50]. However, if a quinone-related mechanism is linked 
to the inhibitory effects of CM363 on cell cycle deserves 
further research. CM363-induced cell cycle arrest was also 
associated with decreased expression levels of p27/KIP 
and Wee1, as expected. The former two act as inhibitors 
of G1 and G2 CDKs, while the latter phosphorylates 
CDK1, inhibiting entry in mitosis. Both p21 and p27 have 
been shown to be required for the assembly of cyclin-
CDK complexes. Therefore, in addition to their known 
action as CDK inhibitors, a certain level of these proteins 
is also required for the correct functioning of cyclin-
CDK complexes essential for progression through the 
cell cycle [19, 50]. As mentioned above, CM363 reduces 
Mcl-1 protein expression in K562 cells. It has been 
reported that some chemotherapy agents enhance Mcl-1 
Figure 8: Phosphoprotein analysis array in CM363-treated K562 cells. (A–C) K562 cultures were incubated with vehicle 
(VEH, □) or CM363 (5 µM, ■) for 6 h. Then, cell whole extracts were analyzed by using the Human Phospho-Kinase Array kit as described 
in Material and Methods. **P < 0.01 versus vehicle-treated cells (VEH); ***P < 0.001 versus vehicle-treated cells (VEH). 
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proteasome degradation resulting in increased expression 
of the double-strand DNA break marker γH2AX, DNA 
damage and apoptosis [22, 23]. In the present study we 
show that CM363 reduces Mcl-1 and increases γH2AX 
after 48 h of treatment which indicates that K562 cells 
cannot overcome cell cycle arrest and they are destined for 
apoptosis. These results further support the hypothesis that 
CM363-induced Mcl-1 downregulation may play a crucial 
role in the mechanism by which CM363 induces apoptosis 
in K562 cells.
The resistance to TKI has produced that many 
researchers focus their efforts on finding new therapies 
or new compounds for use as adjuvants for conventional 
therapy. Targeting Stat5 has become an attractive approach 
to overcome TKI resistances [8–10]. Interestingly, 
in this study we provide evidence that CM363 acts 
synergistically with IM to inhibit Stat5 phosphorylation 
and cell viability in IM-sensitive K562 cells. Moreover, 
we observed that CM363 is equally effective against IM-
sensitive and resistant K562 cells. These results open the 
possibility to use CM363 as coadjuvant therapy in CML. 
Finally, in addition to the in vitro results, when K562 cells 
were implanted in mice, CM363 (10 mg/kg; ip)  potently 
suppressed the growth of tumor xenografts. Therefore, 
CM363 could be of interest in cancer therapy, and several 
observations [34, 36], including this study, argue for its 
potential use in leukemias.
In summary, the present study shows for the first time 
that CM363 is a multi-targeting agent which has potent 
antiCML effects in vitro and in vivo. Reduced survival of 
K562 cells after exposure to CM363 is associated with 
G2-M phase cell cycle arrest and apoptosis. CM363 can 
inhibit cell cycle progression, at least in part, by Chk2 
activation, as well as decresing expression and/or activity 
Figure 9: CM363 modulates survival signaling pathways. K562 cultures were incubated with vehicle (VEH) or CM363 (5 µM) for 
indicated times. Then, immunoblotting analyzes were performed to detect the phosphorylated and total levels of (A) ERK1/2, P38-MAPK, 
JNK and (B) pS6. β-Actin was used as a loading control (VEH: fold 1). Figures are representative of two independent experiments each 
one performed in duplicate.*P < 0.05 versus vehicle-treated cells (VEH, □). **P < 0.01 versus vehicle-treated cells (VEH, □); ***P < 0.001 
versus vehicle-treated cells (VEH, □). 
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Figure 10: Coadministration of CM363/IM interacts synergistically to inhibit pTyr694-Stat5, cell viability in CML and 
to circunvent resistance of CML to IM. (A) K562 cultures were incubated with CM363 (3 or 5 µM), IM (0.05 or 0.1 µM) or both for 
3 h, after which total protein extracts were assayed by immunoblotting using specific antibodies directed against the phosphorylated and 
total forms of Stat5. β-Actin was used as a loading control. (B) K562 cells were cultured in the presence of CM363 (1.2 µM), IM (0.25 µM) 
or both for 48 h, and K562 cells survival were analyzed by the MTT assay. (C) K562 cultures were treated with CM363 (8 doses; from 0 to 
5 µM), IM (8 doses; from 0 to 1 µM) or both in combination (constant ratio combination design (5 (CM363):1 (IM)) for 48 h, after which 
viable cell number was measured by MTT assay as described in Materials and Methods. Isobologram analysis was performed based on 
change in viable cell number for 8 different doses of CM363 and IM using the software Calcusyn® as described in Materials and Methods. 
Data are representative of three independent experiments. (D) The IM sensitive K562 cells (▲,●) and IM-resistant K562-R (∆,○) cells 
were treated with increasing concentrations of CM363 (●,○) or IM (▲, ∆) for 72 h. Then, cell viability was measured by MTT assay as 
described in Materials and Methods. (E) IM sensitive K562  cells (●,○) or IM resistance cells (▲, ∆) were cultured in the absence (vehicle) 
or presence of the indicated concentrations of CM363 over 4-day period. The effects of CM363 on cell proliferation (●,▲) and cytotoxicity 
(○, ∆) were studied by using the Incucyte HD real-time system. Data are represented as area under curve (AUC). Figure is representative 
of two-three independent experiments each one performed in triplicate. ***P < 0.001 versus vehicle treated cells (VEH); $P < 0.001 versus 
CM363 or IM treated cells. 
Figure 11: CM363 inhibits growth of human CML xenografts in vivo. Human K562 cells were inoculated subcutaneously into 
flanks of mice as described in Materials and Methods. Then, mice were divided into three groups of six mice each: vehicle-treated (●), 
CM363 (10 mg/kg/daily; ip) (▲) and IM (40 mg/kg/daily; oral) (■). Volumes of xenograft tumors (A) and body weights (B) were measured 
twice a week. One-way ANOVA followed by Tukey’s multiple comparison tests were used to compare vehicle (control) with drug-treated 
group. *P < 0.05 versus vehicle-treated mice; ***P < 0.001 versus vehicle-treated mice. 
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of cyclin B and Cdc25. Induction of cell cycle arrest and 
apoptosis by CM363 were associated with inhibition of 
Bcr-Abl/Jak2/Stat5 signaling pathway and induction of 
JNK activity. Clinically relevant, the compound potentiates 
the antiproliferative activity of TKI inhibitor IM, circunvent 
IM-resistance in CML cells and suppressed the growth 
of human CML in vivo. Therefore, these data provide 
a rationale for the development of novel NPQ-based 
derivatives as therapeutic agents against human leukemia.
MATERIALS AND METHODS
Ethical statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to the national and international 
guidelines and it has been approved by the authors’ 
institutional review board. All animal experiments 
were performed according to the protocol previously 
approved by the Bioethics Committee of the University of 
Salamanca, according to EU and national laws.
Synthesis of CM363
CM363 [4 - (1, 6, 11 - trioxo - 2,3,4,6,11,12 – 
hexahydro - 1H - benzo [b] xanthen-12-yl) benzonitrile] 
(Figure 1A) was prepared according to EU/USA Patent 
Application PCT/EP2013/065552 (Fused quinonic 
compounds) [17].
Reagents and antibodies
RPMI-1640, DMEM, DMEM-F12, McCoy´s 5A, 
fetal bovine serum (FBS), L-glutamine and PEST (50 units/
ml penicillin, 50 μg/ml streptomycin) were provided by 
Lonza (Belgium). Recombinants human Erytropoyetin 
(EPO) and GH were kindly provided by Roche and Pfizer 
Spain laboratories, respectively. Interleukin-6 (IL6) and 
oncostatin M was provided by Miltenyi Biotec (Gladbach, 
Germany) and HumanZyme (Illinois, USA), respectively. 
The anti-CML drug IM [8] was purchased from Calbiochem 
(San Diego, USA). The origin of the different monoclonal 
and polyclonal antibodies used in the Western blotting 
analyzes were as follows: to pStat5, pBcr, Bcr, pJak2, Jak2, 
pSrc, Src, pERK1/2, ERK1/2, p38-MAPK, pJNK, pAKT, 
AKT, p27, cyclin D3, pRBS780, pRBS807/811, pchk1S296, 
pchk2T68, γH2AX, pS6, S6, cdc25C, Cyclin E, pStat3 
and Stat3 were obtained from Cell Signaling Technology 
(Leiden, The Netherlands). Antibodies against β-actin, Stat5, 
JNK, cyclin B, Wee1, CDK2, Mcl-1, p21, BCL2, GAPDH 
and the horseradish peroxidase-conjugated secondary 
antibodies goat anti-rabbit and goat anti-mouse were 
obtained from Santa Cruz Biotechnologynology (CA, USA). 
Antibodies to caspase-3, -8 and -9 were obtained from Enzo 
Life Sciences (Lausen, Switzerland). Antibodies against 
cytochrome C, cyclin A, PARP, BUBR1 and BCL-X were 
obtained from BD Biosciences (Erembodegem, Belgium). 
Tri-Reagent and other generic chemicals were cited in 
this work were purchased from the Sigma-Aldrich, Roche 
Biochemicals (Mannheim, Germany), or Merck (Darmstadt, 
Germany). Enhanced chemiluminescent detection system 
was provided by Bio-Rad (München, Germany). 
Cells
All cell lines were purchased from the American 
Type Culture Collection (ATCC). The cell lines were 
growth at 37ºC under 5% CO2 under humidified 
atmosphere. The cell lines K562 (derived from patients 
during the blast crisis phase of CML and IM sensitive), 
K562-R (IM resistance human CML) [31], KmycBT15I 
(KBTI; IM resistant human CML, expressing the Bcr-Abl 
T151I  mutant) [32], HEL (human erythroleukemia), HL60 
(human acute myeloid leukemia), MOLM-13 (human acute 
myeloid leukemia), MV4.11 (human acute monocytic 
leukemia), HCT-15 (human colorectal adenocarcinoma), 
PC3 (human prostate cancer), MCF7 (human breast 
cancer), NCTC3749 (mouse lymphoma) as well as the 
MRC.5 cells (non-malignant human lung fibroblasts) 
were maintained in RPMI-1640 medium. The cell lines 
L1210 (mouse lymphocytic leukemia cells), Raw (mouse 
macrophage), HeLa (human epithelial cervix cancer), U-2 
OS (human osteosarcoma), MG63 (human osteosarcoma) 
and T47D (human breast cancer adenocarcinoma) were 
maintained in DMEM. HEK293 cells stably expressing the 
GH receptor (HEKGHR) were maintained in DMEM-F12 
medium [51]. The human breast cancer cell line SKBR3 
was maintained in McCoy´s 5A medium. Cell culture 
medium was supplemented with 10% FBS, L-glutamine 
(2 mM) and PEST. In addition, the cell culture medium for 
T47D was supplemented with 1 mM NaPyr and 10 mM 
HEPES. Human peripheral blood mononuclear cells 
(PBMC) were isolated from heparin-anticoagulated blood 
of healthy volunteers by centrifugation with Ficoll-Paque 
Plus (Amersham Biosciences). 
Cell viability assay
Cells were seeded in 96-well plates (BD Falcon, 
France) at exponential growth density (5000–20000 cells/
well) and treated with vehicle (0.05% DMSO) or 
compound (0.01 to 10 µM) for 48–72 h. The mitochondrial 
metabolization of the tetrazolium salt 3-(4,5-methyltiazol-
2yl-)-2,5diphenyl-tetrazolium bromide] (MTT) 
(Applichen, Germany) was used as indicator of cell 
viability [52]. Optical density was measured at 595 nm 
with the iMark Microplate Reader (BioRad, CA, USA). 
Time-lapse photomicroscopy
Kinetic measurements of cell proliferation and 
cytotoxicity were carried out by using the IncuCyteTM 
HD real time imaging system (Essen BioScience, 
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Hertfordshire, United Kingdom). After seeding in a 
polylysine-coated 96 well-plates [53], K562 cells were 
treated with different concentrations of compound. 
This IncuCyte™ microscope permits the acquisition of 
automated phase contrast images. Individual images are 
processed by an imbedded contrast-based confluence 
algorithm, which compute monolayer confluence for 
each image and at each time point. Multiple images are 
collected per well and averaged to provide a representative 
statistical measure of confluence.
Luciferase reporter gene assay
The HEKGHR cell line was used to determine 
the effects of compounds on GH-regulated Stat5 
transcriptional activity. HEKGHR cells were transfected 
with pSPI-GLE1-Luc (1 μg) overnight using Metafectene 
Pro® (Biontex, Germany).The β-galactosidase expression 
plasmid (0.05 µg) (Thermo Scientific, Illinois, USA)  was 
used for controlling transfection efficiency. The stable 
reporter cell line HeLa/Stat3-luc (Panomics, Fremont, 
USA), was used to determine the effects of compounds 
on oncostatin M-regulated Stat3 transcriptional activity 
[54]. Cells were seeded in a 6-well culture plate (Nunc, 
Denmark) and they were serum deprived (0.5% FBS) 
for 16 h. Then, cells were treated with vehicle (0.05% 
DMSO) or compound (0.1 to 10 µM) during 1 h before 
rhGH (50 nM) [51] or oncostatin M (50 ng/ml) were 
added for 7 h for induction of Stat5- or Stat3-dependent 
transcriptional activities, respectively. Cells were lysed 
in Passive Lysis Buffer and luciferase activity was 
determined by the Luciferase Assay System (Thermo 
Scientific, Illinois, USA). Luciferase activity was 
measured using the microplate reader Fluoroskan Ascent 
FL (Labsystems). Results are expressed as relative 
luciferase units (RLU) per mg of protein content and 
β-galactosidase activity and normalized to those obtained 
for vehicle-treated control cells.
Cell cycle analysis and evaluation of apoptosis
Unsynchronized K562 cells were treated with 
vehicle (0.05% DMSO) or compounds in the presence 
FBS as indicated in figure legends. Then, cells were fixed 
in 70% ethanol and incubated with propidium iodide (PI) 
in the presence of RNAse. Nuclei to the left of the 2N 
peak containing hypodiploid DNA were considered as 
apoptotic. Fluorescent microscopy and flow cytometric 
analysis of PI-stained nuclei were performed to evaluate 
cell cycle and viability by using a FACSCalibur cytometer 
and CellQuest software (BD Biosciences, Erembodegen, 
Belgium) [55]. Apoptosis was also determined by 
translocation of phosphatidylserine to the cell surface 
using the annexin V-FITC apoptosis detection kit (BD 
Pharmingen, Erembodegen, Belgium) according to the 
manufacturer’s protocol.
Stat-DNA binding activity analysis
Cells were treated with vehicle (0.05% DMSO) 
or compounds in the absence FBS as indicated in figure 
legends. Then, cells were rinsed with cold PBS-vanadate 
(1 mM) followed  by harvesting cytosolic and nuclear 
proteins, in the presence of phosphatase and protease 
inhibitor cocktail, by using a Nuclear Extract kit (Active 
Motif Inc., CA, USA) according to the protocol supplied 
by the manufacturer. Stat5- or Stat3-specific DNA-binding 
activities in nuclear extracts were measured by using a 
TransAM STAT kit (Active Motif, CA, USA). Protein 
concentration was measured by the Bio-Rad DC Assay 
(Bio-Rad CA, USA). Absorbance was quantified with the 
iMark Microplate Reader (BioRad, CA, USA).
Immunoblotting
Cells were treated with vehicle (0.05% DMSO) or 
compounds in the presence or absence FBS as indicated 
in figure legends. Then, cells were rinsed with cold 
PBS-vanadate (1 mM) followed by preparation of whole 
lysis extract with RIPA (Pierce, Illinois, USA). Equal 
amounts of each sample were separated by SDS-PAGE 
and transfered onto nitrocellulose membranes. After 
being blocked with 1% BSA-1% Blotto (anti-phospho-
antibodies) (Santa Cruz Biotechnology, CA, USA) or 5% 
blotto (anti-total-antibodies) (Santa Cruz Biotechnology, 
CA, USA) (both diluted in Tris buffered saline with 0.05% 
Tween 20), membranes were immunoblotted overnight at 
4ºC with dilution (1:1000) in the same buffer of blocking 
of primary phosphoprotein or total protein antibodies. 
Antibody-specific labeling was revealed by incubation 
with a HRP-conjugated goat anti-mouse secondary 
antibody (Santa Cruz Biotechnology, CA, USA) or a HRP-
conjugated goat anti-rabbit secondary antibody (Santa 
Cruz Biotech, CA, USA) (1:5000) and visualized with 
the Immu-StarTM WesternCTM kit (Bio-Rad Laboratories, 
CA, USA) using the ChemiDoc XRS system (Bio-Rad 
Laboratories, CA, USA), and the image analysis program 
Quantity one (Bio-Rad Laboratories, CA, USA). To 
control for differences in loading and transfer efficiency 
across membranes, membranes were incubated with a 
monoclonal mouse anti-beta actin antibody (Santa Cruz 
Biotechnology, CA, USA) [56]. The phosphoprotein 
array analysis of K562 cells was carried out by using the 
Profiler Human Phospho-Kinase Array Kit ARY003B 
(R&D Systems, Minneapolis, MN, USA) according to the 
manufacturer`s instructions.
Gene expression analysis by real-time 
quantitative PCR (qPCR)
K562 cells (0.3 × 106 cells/ml) were treated 
with vehicle (0.05% DMSO, final concentration) or 
compounds, in the presence of FBS, as indicated in 
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figure legends. The mRNA expression levels of genes 
were measured using qPCR as previously described [57]. 
Briefly, total RNA was isolated by homogenization of 
cells with TriReagent (Sigma, St. Louis, MO) according 
to the protocol supplied by the manufacturer. RNA yields 
were measured by UV absorbance and the quality of total 
RNA was analyzed by using an Experium (BioRad). All 
samples were treated with RNAse-free DNase (Promega, 
Madison, WI) and 2 µg of total RNA was reverse 
transcribed by using an iScriptTM kit (BioRad, CA, 
USA). Two microliters of cDNA served as a template in 
a 20-µl qPCR reaction mix containing the primers and 
SYBR Green PCR Master mix (Diagenode, Belgium). 
Quantification of the gene expression was performed with 
an ABI PRISM7000 SD PCR System. A relative standard 
curve was constructed with serial dilutions (1:1, 1:2, 1:4, 
1:8) using a pool of the cDNA generated from all groups 
used in the study. The amplification program consisted of 
1 cycle of 95°C for 10 min, followed by 45 cycles of 95°C 
for 15 sec, annealing for 10 sec, and 72°C for 30 sec. The 
fluorescent intensity was measured at a specific acquisition 
temperature for each gene. A dissociation protocol was 
performed to assess the specificity of the primers and the 
uniformity of the PCR generated products. Data were 
extracted and amplification plots generated with ABI SDS 
software. All amplifications were performed in triplicate, 
and Ct scores were averaged for subsequent calculations of 
relative expression values. The level of individual mRNA 
measured by qPCR was normalized to the level of the 
housekeeping gene GAPDH by using the Pfaffl method 
[58]. Exon-specific primers (Table 2) were designed by the 
Primer 3 program [59].
Drug combination analysis
The endpoint for these analyzes was derived from 
MTT assays incorporating a third set of replicates, where 
cells were exposed to constant-ratio combinations of the 
test drug CM363 with IM. K562 cells were exposed to 
doubling dilutions of the individual drugs over a wide 
range. The degree of inhibition of cell viability in these 
assays relative to unexposed controls was designed the 
effect, which ranged from 0 (no inhibition) to 1 (cell 
death). The effects of the drug treatments were plotted 
and analyzed to produce computed estimations of the 
relative responses to either drugs alone or in combination. 
In this way, it is possible to detect synergistic, additive or 
antagonistic effects. Triplicate independent experiments 
were set up for each K562 cells/drug combination. In each 
case the analysis generates plots of Combination Index 
(CI) versus effect. The combination indexes (CI) less 
than 1, equal to 1, and greater than 1 indicate synergism, 
additive, and antagonism between the drugs, respectively. 
The CI curves can be represented as the average CI values 
at effects of 0.20, 0.50, 0.70 and 0.9 (IC20, IC50, IC70 
and IC90, respectively). The dose-effect curves of single 
or combined drug treatment were analyzed by the median-
effect method of Chou and Talalay using the Calcusyn 
Software (Biosoft, Cambridge, UK) [30].
Antileukemic activity of CM363 in xenograft 
mice tumors
Six weeks old female athymic mice (NOD-SCID), 
were purchased from Charles River River (Barcelona, 
Spain), and were housed in a specifically designed 
pathogen-free isolation facility as reported previously [33]. 
The mice were subcutaneously inoculated into the right 
flank with 2.5 × l06 K562 cells in 100 µL of RPMI-1640 
medium and 100 µL of Matrigel. When tumors became 
palpable, mice were randomized into three groups (n = 8 
per group); the control group (receiving vehicle alone- 
DMSO: PEG-400: sterile water at 5:25:70 (w/v)), the 
group receiving CM363 10 mg/Kg or the group receiving 
the positive control IM 40 mg/kg. The vehicle and CM363 
treatments were administered via intraperitoneal injection 
(i.p.) every day except Saturday and Sunday. While IM 
was administered orally using the same schedule. The 
study was conducted over a 25 days period. Caliper 
measurements of the tumor diameters were performed 
twice per week, and the tumor volume was estimated as 
the volume of an ellipse using the following formula: 
V = 4/3n × (a/2) × (b/2)2, where a and b correspond to 
the longest and shortest diameter, respectively. Mice 
were sacrificed when their tumor diameters reached 2 cm, 
or when they became moribund. Differences in tumor 
volumes between control and treated group were evaluated 
using the Mann-Whitney test. 
Statistical analysis
The significance of differences between groups 
was tested by one-way ANOVA, followed by post hoc 
comparisons of group means according to the GraphPad 
Prism 5 program (GraphPad Software, San Diego, CA). 
Statistical significance was reported if P < 0.05 was 
achieved. For graphing purposes in the qPCR analysis, 
the relative expression levels were scaled so that the 
Table 2: Gene names and primer sequences (5ʹ- 3ʹ) used for real-time PCR
Gene bank Gene Product Gene Forward primer Reverse primer
NM_002467.4 myelocytomatosis oncogene Myc CCAGCAGCGACTCTGAGG CCAAGACGTTGTGTGTTC
NM_002648.3 serine/threonine kinase Pim GCTCGGTCTACTCAGGCATC CATTAGGCAGCTCTCCCCAG
NM_001289746.1 glyceraldehyde-3P-dehydrogenase GAPDH CCATGGAGAAGGCTGGGG CAAAGTTGTCATGGATGACC
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expression level of the vehicle-treated control group 
equalled one. The concentration required to reduce cell 
viability/proliferation by 50% (IC50) was determined 
graphically using the curve fitting algorithm of the 
GraphPad Prism 5. Values are means ± SEMs from three 
independent experiments, each performed in triplicate. 
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